Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04059523 · ClinicalTrials.gov registry record · Phase 1
MUSE Study to Evaluate the Pharmacokinetics, Safety and Tolerability of S6G5T-3
A Phase 1 study, sponsored by Sol-Gel Technologies.
- Completed
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
NCT04059523: Completed Phase 1 study, sponsored by Sol-Gel Technologies.
NCT04059523 is a Phase 1 study that has completed, run by Sol-Gel Technologies. The registered enrollment target is 62 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04059523, a Phase 1 study, has completed, sponsored by Sol-Gel Technologies.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
Study Summary
To assess the degree of systemic exposure of S6G5T-3 compared to the Reference Listed Drug (RLD) Retin-A® 0.1% Cream when applied topically once daily for 14 days, under maximal use conditions in adolescents ≥12 years of age and adults with acne vulgaris.
Primary Outcome
The degree of systemic exposure of S6G5T-3 compared to the Reference Listed Drug (RLD) when applied topically once daily for 14 days, under maximal use conditions in subjects with acne vulgaris. Cmax = Maximum plasma concentration will be calculated
Interventions
- DRUG S6G5T-3
- DRUG Retin-A® 0.1% Cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2019-06-27 |
| Est. Completion | 2020-02-06 |
| Phase | Phase 1 |
What the finished NCT04059523 record still lists
NCT04059523 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which S6G5T-3 is the first listed.
NCT04059523 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04059523 about?
NCT04059523 is a clinical study titled "MUSE Study to Evaluate the Pharmacokinetics, Safety and Tolerability of S6G5T-3". To assess the degree of systemic exposure of S6G5T-3 compared to the Reference Listed Drug (RLD) Retin-A® 0.1% Cream when applied topically once daily for 14 days, under maximal use conditions in adolescents ≥12 years of age and adults with acne vulgaris.
What is the current status of trial NCT04059523?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2019-06-27. Estimated completion is 2020-02-06.
What interventions are being tested in trial NCT04059523?
The interventions under investigation include: S6G5T-3 (DRUG), Retin-A® 0.1% Cream (DRUG).
Who is sponsoring clinical trial NCT04059523?
This trial is sponsored by Sol-Gel Technologies, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04059523's enrollment target sits among peer trials
62 824th of 2000 higher than 1,173 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI